|Abbott's HUMIRA Receives U.S. FDA Approval; Progenics Initiates Phase 2 Clinical Trial of PSMA ADC|
|By Staff and Wire Reports|
|Friday, 28 September 2012 19:32|
Abbott (NYSE: ABT) announced the U.S. FDA has approved HUMIRA® (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.
Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary diseases that comprise inflammatory bowel disease (IBD).
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) has opened enrollment in a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing drug to malignant cells.
"New prostate cancer therapies are in high demand. Patients with advanced, hormone-refractory prostate cancer typically do not survive more than 12 to 18 months," said Daniel Petrylak, M.D., Director of the Prostate Cancer Program/Genitourinary Cancer Program and Co-Director of the Signal Transduction Program at Yale University Medical Center. "The hope for PSMA ADC is that its targeted therapeutic approach could be more effective and cause fewer toxic side-effects in treating cancer." Dr. Petrylak participated as an Investigator in the phase 1 trial of PSMA ADC and is continuing his evaluation of PSMA ADC in this phase 2 study.
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the special committee of independent directors (the "Independent Committee") has retained Jefferies & Company, Inc. as the Independent Committee's financial advisor.
BIOLASE, Inc. (NASDAQ: BIOL), the World's leading biological dental laser manufacturer and distributor, today announced that Frederick Furry, Chief Operating Officer and Chief Financial Officer, will make an investor presentation at the LD Micro Summit on Thursday, October 4, 2012, at 1 PM Pacific Time.
Cytomedix, Inc. (OTCQX: CMXI) (the "Company"), a leading developer of biologically active regenerative therapies, today announced that a poster presentation highlighting the clinical merits of the Company's Angel® Whole Blood Processing System's Platelet Rich Plasma ("PRP") in facial rejuvenation was presented at the British Association of Aesthetic Plastic Surgeons Annual Scientific Meeting held in London from September 20 to 21, 2012.
EasyMed Services Inc. (CNSX:EZM)(OTCBB:EMYSF)(MUN:EY6) ("EasyMed" or the "Company") reports the following update to shareholders on material events that impact the trading of EasyMed in the United States public markets.
Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of data that support expanded use of the OncotypeDX®tests in optimizing treatment decisions for breast and colon cancer patients at various stages of disease.
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced that it has priced a direct public offering of approximately 6.3 million shares of its Common Stock to certain affiliates of Ayer Capital, RA Capital and Quaker Partners, at a price of $4.07 per share, which was the consolidated closing bid price on the NASDAQ Capital Market on September 27, 2012, with gross proceeds to Insmed of $25.7 million.
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial results for the quarter and year ended June 30, 2012.
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) today announced the appointment of Dr. Alan Tuchman to the role of Chief Medical Officer and Senior Vice President, Clinical and Medical Development.
Power of the Dream Ventures, Inc. (OTCBB: PWRV) is pleased to announce the acquisition of Genetic Immunity, Inc., a Phase III clinical stage biotechnology company with experimental nanomedicines that will lead to the next generation of immunotherapies, in a market that is projected to reach $11.00 billion by 2018.
Regenerative medicine company Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) announced that it has been awarded a grant of an additional US$880K in support for its on-going pivotal US FDA trial for the use of ReCell® Spray-On-Skin® in the treatment of burn injuries.
Unilens Vision Inc. (OTCQB: UVIC) (TSX VENTURE: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for FY2012.